🚨 Results from #LITESPARK022 (#LS022) are out in @NEJM!
1/This phase III trial evaluated whether adding the HIF-2α inhibitor Belzutifan (BEL) to adjuvant pembrolizumab (PEMBRO) could improve outcomes for patients with resected clear-cell RCC at increased risk for recurrence.
https://t.co/1BLAercj3p
@oncoalert@asco@myESMO
#WorldCancerDay | #UnitedByUnique
Cancer challenges more than the body it tests families, systems, and equity.
We believe in
🌍 Access beyond geography
🧬 Precision over guesswork
🤝 Patients as partners
💙 Science with compassion
Awareness isn’t enough.
#WorldCancerDay2026
More evidence that #immunotherapy works better in the morning.
In a prospective, randomized phase III trial, giving first-line chemo-immunotherapy earlier in the day (<15:00) nearly doubled PFS (11.3 vs 5.7 mo, HR 0.40) and improved OS (28.0 vs 16.8 mo; HR 0.42) in advanced NSCLC.
More effective, no added cost and easy to implement.
Likely reflects circadian immune rhythms with greater CD8⁺ activation and less T-cell exhaustion.
https://t.co/q4JrFU4yws @OncoAlert
ADCs are like Trojan horses. 👉🚨🔥They exploit cell surface receptors to internalise chemo payloads into cancer cells. Next generation therapies. Enhertu shows responses in leptomeningeal disease. 🎯
https://t.co/P3Es65UqNw
If you need guidance on all the complexities on how to treat patients with NSCLC with or without driver alterations then:
Who you gonna ask? Ask ASCO of course!
Updated living @ASCO guidelines are out and they come along with
☑️slides
☑️podcast
☑️recommendations table
☑️algorithm
☑️pocket card
☑️and patient information!
These guidelines have everything- check them out!
Amazing work by team leads- @LudaBazhenovaMD@Sonampuri Natasha Leighl, Josh Reuss and ASCO champion, Nofisat Ismaila!
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
It was presented at #ASCO25 and is worth highlighting again: Encorafenib + Cetuximab + FOLFOX doubled OS
https://t.co/Y3NfyreaOW
Outstanding international @WIN_Consortium MTB with discussion of difficult cases of glioblastoma & breast cancer including with brain metastases & various driver molecular alterations that are amenable to targeted therapy combinations @Dr_R_Kurzrock@SewantiLimaye@WIN_Consortium
Amazing international WIN MTB. Cases presented today by Sewanti Limaye, MD— leading precision oncologist from India.
All under the leadership of Wafik El Deiry.
Bringing experts from around the globe together to help patients.
@weldeiry@SewantiLimaye